Cardiogenic Shock - Pipeline Insight - 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Cardiogenic Shock – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cardiogenic Shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cardiogenic Shock: Overview
Cardiogenic shock is defined as systemic tissue hypoperfusion due to inadequate cardiac output (CO) despite adequate circulatory volume. Cardiogenic shock is a serious condition that occurs when your heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Cardiogenic shock is considered a medical emergency and should be treated immediately. The most common cause of cardiogenic shock is a heart attack. Other health problems that may lead to cardiogenic shock include heart conditions such as heart failure, chest injuries, medicine side effects, and conditions that prevent blood from flowing freely through your heart, such as a blood clot in the lungs.
Symptoms
The symptoms of Cardiogenic Shock include:
Inotropes and vasopressors are the initial therapies for supporting patients with Cardiogenic Shock. All the inotropic agents, except for, levosimendan, work by increasing cyclic adenosine monophosphate (cAMP) levels which in-turn activates protein kinase A with resultant increased intracellular calcium. Temporal Mechanical Circulatory System is an integral part of management of Cardiogenic Shock and is commonly utilized as a bridge-to-decision, whether it is recovery, palliation, heart transplant or a durable MCS device. Emergent revascularization is the only therapy that has been shown to reduce mortality in patients with cardiogenic shock complicating acute myocardial Infarction.
Cardiogenic Shock Emerging Drugs Chapters
This segment of the Cardiogenic Shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cardiogenic Shock Emerging Drugs
Further product details are provided in the report
Cardiogenic Shock: Therapeutic Assessment
This segment of the report provides insights about the different Cardiogenic Shock drugs segregated based on following parameters that define the scope of the report, such as:
Cardiogenic Shock: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cardiogenic Shock therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cardiogenic Shock drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cardiogenic Shock – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cardiogenic Shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cardiogenic Shock: Overview
Cardiogenic shock is defined as systemic tissue hypoperfusion due to inadequate cardiac output (CO) despite adequate circulatory volume. Cardiogenic shock is a serious condition that occurs when your heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Cardiogenic shock is considered a medical emergency and should be treated immediately. The most common cause of cardiogenic shock is a heart attack. Other health problems that may lead to cardiogenic shock include heart conditions such as heart failure, chest injuries, medicine side effects, and conditions that prevent blood from flowing freely through your heart, such as a blood clot in the lungs.
Symptoms
The symptoms of Cardiogenic Shock include:
- Low blood pressure, dizziness
- Confused and nauseous
- Breathing problems
- Bulging of large veins in the neck
- Cold hands and feet
- Loss of consciousness
- Swelling of feet
- Cardiogenic shock is usually diagnosed in an emergency setting. Electrocardiogram is used to record the electrical activity of heart via electrodes attached to skin. Echocardiogram records sound waves which produces an image of the heart that can help identify damage from a heart attack. Invasive haemodynamic assessment using pulmonary artery catheterization is not recommended for routine use, but is useful to confirm and characterize suspected shock, and is often used to manage refractory cardiogenic shock.
Inotropes and vasopressors are the initial therapies for supporting patients with Cardiogenic Shock. All the inotropic agents, except for, levosimendan, work by increasing cyclic adenosine monophosphate (cAMP) levels which in-turn activates protein kinase A with resultant increased intracellular calcium. Temporal Mechanical Circulatory System is an integral part of management of Cardiogenic Shock and is commonly utilized as a bridge-to-decision, whether it is recovery, palliation, heart transplant or a durable MCS device. Emergent revascularization is the only therapy that has been shown to reduce mortality in patients with cardiogenic shock complicating acute myocardial Infarction.
Cardiogenic Shock Emerging Drugs Chapters
This segment of the Cardiogenic Shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cardiogenic Shock Emerging Drugs
- Istaroxime: Windtree Therapeutics
Further product details are provided in the report
Cardiogenic Shock: Therapeutic Assessment
This segment of the report provides insights about the different Cardiogenic Shock drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cardiogenic Shock
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cardiogenic Shock: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cardiogenic Shock therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cardiogenic Shock drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cardiogenic Shock R&D. The therapies under development are focused on novel approaches to treat/improve Cardiogenic Shock.
- Cardiogenic Shock Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cardiogenic Shock drugs?
- How many Cardiogenic Shock drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cardiogenic Shock?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cardiogenic Shock therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cardiogenic Shock and their status?
- What are the key designations that have been granted to the emerging drugs?
- Windtree Therapeutics
- Leading BioSciences
- Istaroxime
- Tranexamic acid
Introduction
Executive Summary
Cardiogenic Shock: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cardiogenic Shock – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cardiogenic Shock companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cardiogenic Shock Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Istaroxime: Windtree Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Cardiogenic Shock Key Companies
Cardiogenic Shock Key Products
Cardiogenic Shock- Unmet Needs
Cardiogenic Shock- Market Drivers and Barriers
Cardiogenic Shock- Future Perspectives and Conclusion
Cardiogenic Shock Analyst Views
Cardiogenic Shock Key Companies
Appendix
Executive Summary
Cardiogenic Shock: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cardiogenic Shock – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cardiogenic Shock companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cardiogenic Shock Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Istaroxime: Windtree Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Cardiogenic Shock Key Companies
Cardiogenic Shock Key Products
Cardiogenic Shock- Unmet Needs
Cardiogenic Shock- Market Drivers and Barriers
Cardiogenic Shock- Future Perspectives and Conclusion
Cardiogenic Shock Analyst Views
Cardiogenic Shock Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cardiogenic Shock
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cardiogenic Shock
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cardiogenic Shock
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cardiogenic Shock
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
